Nuclear Medicine Theranostics: Perspective from Pakistan

  • Humayun BashirEmail author
  • M. Numair Younis
  • M. Rehan Gul


Nuclear medicine has been offering diagnostic and therapeutic solution since the introduction of radioactive iodine for thyroid diseases since decades. However, the concept of theranostics has given a new found impetus to the use of pairs of radiopharmaceuticals for diagnosis and treatment. Presented here is a perspective on theranostics from Pakistan.


Theranostics Ga68 Lu177 DOTATATE Hybrid imaging Pakistan 


Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no conflict of interest.

Ethical Approval

All procedures quoted in the review articles involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Informed Consent

Informed content data exists for the quoted procedures in this review article.


  1. 1.
    Younis N, Bashir H. Theranostics–neuroendocrine tumours. J Cancer Allied Spec. 2018;4(2):1.Google Scholar
  2. 2.
    Sawin CT, Becker DV. Radioiodine and the treatment of hyperthyroidism: the early history. Thyroid. 1997;7:163–76.CrossRefGoogle Scholar
  3. 3.
    Sharp SE, Trout AT, Weiss BD, Gelfand MJ. MIBG in neuroblastoma diagnostic imaging and therapy. Radiographics. 2016;36:258–78.CrossRefGoogle Scholar
  4. 4.
    Ahmadzahehfar H, Sabet A, Wilhelm K, Biersack HJ. Iodine-131-lipiodol therapy in hepatic tumours. Methods. 2011;55:246–52.CrossRefGoogle Scholar
  5. 5.
    Rizzieri D. Z. (ibritumomabtiuxetan) after more than a decade of treatment experience, what have we learned. Crit Rev OncolHematol. 2016;105:5–17.CrossRefGoogle Scholar
  6. 6.
    Handkiewicz-Junak D, Poeppel TD, Bodei L, Aktolun C, Ezziddin S, Giammarile F, et al. EANM guidelines for radionuclide therapy of bone metastases with beta-emitting radionuclides. Eur J Nucl Med Mol Imaging. 2018;45:846–59.CrossRefGoogle Scholar
  7. 7.
    Kunikowska J, Lewington V, Krolicki L. Optimizing somatostatin receptor imaging in patients with neuroendocrine tumors: the impact of 99mTc-HYNICTOC SPECT/SPECT/CT versus 68Ga-DOTATATE PET/CT upon clinical management. Clin Nucl Med. 2017;42:905–11.CrossRefGoogle Scholar
  8. 8.
    Ajit S. Rhenium 188: the poor Man’s yttrium. World J Nucl Med. 2017;16:1–2.CrossRefGoogle Scholar
  9. 9.
    Zaman MU, Fatima N, Sajjad Z, Hashmi I. High-dose I131 therapy on outpatient basis: imperative and no more a desire. Pak J Nucl Med. 2012;2:92–7.Google Scholar
  10. 10.
    Memon AS, Laghari NA, Mangi FH, Hussain MM, Nohario SH. Isolation period of 131I administered patients at NIMRA Jamshoro Pakistan. Int J Radiol Radiat Ther. 2017;2:2–5.Google Scholar
  11. 11.
    Hassan A, Siddique M, Bashir H, Riaz S, Wali R, Mahreen A, et al. 18F-FDG PET-CT imaging versus bone marrow biopsy in pediatric Hodgkin’s lymphoma: a quantitative assessment of marrow uptake and novel insights into clinical implications of marrow involvement. Eur J Nucl Med Mol Imaging. 2017;44:1198–206.CrossRefGoogle Scholar
  12. 12.
    Riaz S, Bashir H, Niazi IK. Triage of limited versus extensive disease on F18 FDG PET/CT scan in small cell lung cancer Asia Ocean. J Nucl Med Biol. 2017;5:109–13.Google Scholar
  13. 13.
    Riaz S, Bashir H, Hassan L, Jamshed A, Murtaza A, Hussain R. Impact and prognostic value of 18F FDG PET-CT scan in the evaluation of residual head and neck cancer - single centre experience from Pakistan. South Asian J Cancer. 2017;6:81–3.Google Scholar
  14. 14.
    Zaman MU, Fatima N, Zaman A, et al. Significantly low effective dose from 18FDG PET/CT scans using dose reducing strategies: “lesser is better”. Asian Pac J Cancer Prev. 2016;17:3465–8.Google Scholar
  15. 15.
    Riaz S, Nawaz MK, Faruqui ZS, Kazmi AS, Loya A, et al. Diagnostic accuracy of 18F-FDG PET-CT in the evaluation of carcinoma of unknown primary. Mol Imaging Radionucl Ther. 2016;25:1–10.CrossRefGoogle Scholar
  16. 16.
    Bodei L, Brand MJ, Baum RP, Pavel ME, Horsch D, O’Dorisio MS, et al. The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2013;40:800–16.CrossRefGoogle Scholar
  17. 17.
    Strosberg J, El-Haddad G, Wolin E, Hendifar A, Chasen B, Mittra E, et al. Phase 3 trial of 177Lu-dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017;376:125–35.CrossRefGoogle Scholar
  18. 18.
    Strosberg J, Wolin E, Chasen B, Kulke M, Bushnell D, Caplin M, et al. Health-related quality of life in patients with progressive midgut neuroendocrine tumors treated with 177Lu-dotatate in the phase III NETTER-1 trial. J Clin Oncol. 2018;36:2578–84.CrossRefGoogle Scholar
  19. 19.
    Mittra ES. Neuroendocrine tumor therapy: 177Lu-DOTATATE. Am J Roentgenol. 2018;211:278–85.CrossRefGoogle Scholar
  20. 20.
    Virgolini I, Decristoforo C, Haug A, Fanti S, Uprimny C. Current status of theranostics in prostate cancer. Eur J Nucl Med Mol Imaging. 2018;45:471–95.CrossRefGoogle Scholar
  21. 21.
    Hofman MS, Violet J, Hicks RJ, Ferdinandus J, Thang SP, Akhurst T, et al. [177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study. Lancet Oncol. 2018;19:825–33.CrossRefGoogle Scholar
  22. 22.
    Gavan SP, Thompson AJ, Payne K. The economic case for precision medicine. Expert Rev Precis Med Drug Dev. 2018;3:1–9.CrossRefGoogle Scholar
  23. 23.
    Ajit S. An overview of nuclear medicine and PET CT in India. Curr Trends Clin Med Imaging. 2017;1(5).Google Scholar
  24. 24.
    Atutornu J, Hayre CM. Personalized medicine and medical imaging: opportunities and challenges for contemporary health care. J Med Imaging Radiat Sci. 2018;49:352–9.CrossRefGoogle Scholar

Copyright information

© Korean Society of Nuclear Medicine 2019

Authors and Affiliations

  1. 1.Nuclear Medicine DepartmentShaukat Khanum Memorial Cancer Hospital and Research Centre (SKMCH& RC)LahorePakistan
  2. 2.Nuclear Medicine departmentInstitute of Nuclear Medicine Lahore (INMOL)LahorePakistan

Personalised recommendations